In future work, the MDL-CA framework will be extended to support multi-class classification, enabling the identification of clinically relevant brain tumor subtypes, such as IDH mutation status or MGMT promoter methylation, which are essential for personalized treatment planning. Here, MGMT is linked to brain neoplasm.